ID   Ma-Mel-54b
AC   CVCL_C288
DR   cancercelllines; CVCL_C288
DR   ESTDAB; ESTDAB-215
DR   GEO; GSM2545604
DR   Progenetix; CVCL_C288
DR   Wikidata; Q54903815
RX   PubMed=28561041;
CC   Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Gln959Pro (c.2876A>C); Zygosity=Homozygous (PubMed=28561041).
CC   Omics: SNP array analysis.
CC   Derived from site: Metastatic; Cutaneous; UBERON=UBERON_0000014.
ST   Source(s): ESTDAB=ESTDAB-215
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 12,13
ST   D3S1358: 14,16
ST   D5S818: 12,13
ST   D7S820: 12,13
ST   FGA: 22
ST   TH01: 6,9.3
ST   TPOX: 8,11
ST   vWA: 15,18
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_A189 ! Ma-Mel-54a
SX   Female
AG   41Y
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 02-05-24; Version: 12
//
RX   PubMed=28561041; DOI=10.1038/ncomms15440; PMCID=PMC5460020;
RA   Sucker A., Zhao F., Pieper N., Heeke C., Maltaner R., Stadtler N.,
RA   Real B., Bielefeld N., Howe S., Weide B., Gutzmer R., Utikal J.S.,
RA   Loquai C., Gogas H., Klein-Hitpass L., Zeschnigk M., Westendorf A.M.,
RA   Trilling M., Horn S., Schilling B., Schadendorf D., Griewank K.G.,
RA   Paschen A.;
RT   "Acquired IFNgamma resistance impairs anti-tumor immunity and gives
RT   rise to T-cell-resistant melanoma lesions.";
RL   Nat. Commun. 8:15440.1-15440.15(2017).
//